Receives U.S. Patent for Groundbreaking Treatment for Opioid Use DisorderClinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 ...

Cash and Cash Equivalents: As of March 31, 2025, the company had cash and cash equivalents of $13.9 million, compared to $23.3 million as of December 31, 2024. The company believes its cash balance as ...

Mineralys Therapeutics, Inc. ( NASDAQ: MLYS) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET ...

First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinica ...

Just about everyone in the state is watching to see whether our state legislature can pull off tort reform or any meaningful ...